ArticleFrontiers in medicine2025
Combined bailing capsule and conventional therapies in the treatment of chronic renal failure: a meta-analysis and economic evaluation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bailing capsules are currently recommended for improving renal function in patients with chronic renal failure (CRF) in China. However, limited research assesses the clinical benefits of Bailing capsules in the context of healthcare resource utilization. Therefore, we conducted this study to compare the efficacy of Bailing capsules combined with conventional therapies and to assess their economic value from the Chinese healthcare system perspective. Methods: For the meta-analysis, six bibliographic databases were systematically searched for eligible randomized controlled trials (RCTs) from their inception until May 2025. For the economic evaluation, a Markov model was established to simulate the disease progression of patients over 20 years. The incremental cost-effectiveness ratio (ICER) was measured, and one-way and probabilistic sensitivity analyses were performed to observe model stability. Results: The use of Bailing capsules combined with conventional therapies was associated with a significant reduction in serum creatinine compared to conventional therapies alone (weighted mean difference [WMD]: -36.73 μmol/L; 95% confidence interval [CI]: -45.06 to -28.40; Discussion: Bailing capsules combined with conventional therapies are associated with a greater reduction in serum creatinine and are likely to be cost-effective for patients with CRF in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.